Abstract: The newly released 2025 American College of Gastroenterology (ACG) Clinical Guideline for the Management of Adults with Crohn's Disease introduces important updates in methodology, diagnostic logic, therapeutic goals, and treatment strategies. The updated guideline emphasizes that symptoms should be attributed to disease activity only after verification by objective evidence such as endoscopy or imaging. Therapeutic goals have been expanded from solely pursuing mucosal healing to equally emphasizing clinical remission, endoscopic remission, and improvement in quality of life. In terms of treatment strategy, the guideline clearly advocates for early initiation of biologic agents in newly diagnosed patients with moderate-to-severe disease, promoting a top-down approach. Regarding stricturing disease, breaking the previous concept that strictures are irreversible, the guideline proposes that inflammationpredominant strictures can be improved with intensified medical therapy. For selected patients with localized disease, early ileocecal resection is listed as a reasonable first-line alternative to anti-TNF therapy. The new guideline provides a more evidence-based and forward-looking management framework for the clinical diagnosis and treatment of Crohn's disease, offering important practical guidance for advancing individualized precision medicine.